Novartis keeps a close eye on gene therapy with Vedere Bio buyAlready a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 Share XNovartis keeps a close eye on gene therapy with Vedere Bio buyhttps://pharmaphorum.com/news/novartis-keeps-a-close-eye-on-gene-therapy-with-vedere-bio-buy/
BMS joins forces with insitro to develop neurodegenerative treatmentsinsitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies Share XBMS joins forces with insitro to develop neurodegenerative treatmentshttps://pharmaphorum.com/news/bms-joins-forces-with-insitro-to-develop-neurodegenerative-treatments/
NICE talking to you: Trends in early HTA engagementWith exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are Share XNICE talking to you: Trends in early HTA engagementhttps://pharmaphorum.com/views-analysis-market-access/nice-talking-to-you/
US buys Lilly COVID antibody, as effectiveness questions remainThe US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million Share XUS buys Lilly COVID antibody, as effectiveness questions remainhttps://pharmaphorum.com/news/us-buys-300000-doses-lilly-covid-antibody/
Exact Sciences buys cancer detection company Thrive for $2.15 billionStocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK Share XExact Sciences buys cancer detection company Thrive for $2.15 billionhttps://pharmaphorum.com/news/exact-sciences-buys-early-cancer-detection-company-thrive-for-2-15-billion/
COVID-19 bites into Pfizer’s Q3, but biopharma revenues risePfizer is one of the front-runners in the race to approve a COVID-19 vaccine but the US company Share XCOVID-19 bites into Pfizer’s Q3, but biopharma revenues risehttps://pharmaphorum.com/news/covid-bites-into-pfizers-q3-but-biopharma-revenues-rise/
Catabasis craters after giving up on muscular dystrophy leadCatabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after Share XCatabasis craters after giving up on muscular dystrophy leadhttps://pharmaphorum.com/news/catabasis-craters-after-giving-up-on-muscular-dystrophy-lead/
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trialEli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run Share XNIAID drops Lilly antibody from ACTIV-3 COVID-19 trialhttps://pharmaphorum.com/news/niaid-drops-lilly-antibody-from-activ-3-covid-19-trial/
What can we learn from women’s health data?Analysing real-world health data could help overcome the bias towards men in traditional medical research, says Sensyne Health’s Share XWhat can we learn from women’s health data?https://pharmaphorum.com/views-analysis-digital/what-can-we-learn-from-womens-health-data/
